StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.71−2.74 (-2.55%)

Close on Nov 17, 2026Market cap $181.19BP/E 33.7Yield 2.29%

Abbott Laboratories operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Abbott Laboratories's operating cash flow for the twelve months ending Jun 30, 2026 was $9.91B, up 9.6% year over year. For fiscal 2025 it was $9.57B, up 11.8% from the year before. Over ten years it grew 12.4% a year on average. The highest annual figure on record is $10.53B in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.57B+11.8%
FY2024Dec 31, 2024$8.56B+17.9%
FY2023Dec 31, 2023$7.26B-24.2%
FY2022Dec 31, 2022$9.58B-9.0%
FY2021Dec 31, 2021$10.53B+33.3%
FY2020Dec 31, 2020$7.90B+28.8%
FY2019Dec 31, 2019$6.14B-2.6%
FY2018Dec 31, 2018$6.30B+13.1%
FY2017Dec 31, 2017$5.57B+73.9%
FY2016Dec 31, 2016$3.20B+8.0%
FY2015Dec 31, 2015$2.97B-19.3%
FY2014Dec 31, 2014$3.68B+10.6%
FY2013Dec 31, 2013$3.32B-64.3%
FY2012Dec 31, 2012$9.31B+3.8%
FY2011Dec 31, 2011$8.97B+2.7%
FY2010Dec 31, 2010$8.74B+20.1%
FY2009Dec 31, 2009$7.28B+4.0%
FY2008Dec 31, 2008$6.99B+34.9%
FY2007Dec 31, 2007$5.18B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.49B+21.5%
Q1 FY2026Mar 31, 2026$1.32B-7.2%
Q4 FY2025Dec 31, 2025$3.32B+15.6%
Q3 FY2025Sep 30, 2025$2.79B+3.0%
Q2 FY2025Jun 30, 2025$2.05B+4.4%
Q1 FY2025Mar 31, 2025$1.42B+38.2%
Q4 FY2024Dec 31, 2024$2.87B-5.6%
Q3 FY2024Sep 30, 2024$2.71B+44.1%
Q2 FY2024Jun 30, 2024$1.96B+62.9%
Q1 FY2024Mar 31, 2024$1.03B-10.3%
Q4 FY2023Dec 31, 2023$3.04B+30.6%
Q3 FY2023Sep 30, 2023$1.88B-32.5%
Q2 FY2023Jun 30, 2023$1.20B-50.1%
Q1 FY2023Mar 31, 2023$1.14B-44.6%
Q4 FY2022Dec 31, 2022$2.33B-24.2%
Q3 FY2022Sep 30, 2022$2.78B+2.9%
Q2 FY2022Jun 30, 2022$2.41B+13.3%
Q1 FY2022Mar 31, 2022$2.07B-21.7%
Q4 FY2021Dec 31, 2021$3.07B-19.2%
Q3 FY2021Sep 30, 2021$2.70B+30.7%
Q2 FY2021Jun 30, 2021$2.13B+61.0%
Q1 FY2021Mar 31, 2021$2.64B+268.8%
Q4 FY2020Dec 31, 2020$3.80B+57.2%
Q3 FY2020Sep 30, 2020$2.07B+6.1%
Q2 FY2020Jun 30, 2020$1.32B+24.7%
Q1 FY2020Mar 31, 2020$715.00M+0.4%
Q4 FY2019Dec 31, 2019$2.42B+36.9%
Q3 FY2019Sep 30, 2019$1.95B-10.8%
Q2 FY2019Jun 30, 2019$1.06B-14.8%
Q1 FY2019Mar 31, 2019$712.00M-35.7%
Q4 FY2018Dec 31, 2018$1.77B+7.6%
Q3 FY2018Sep 30, 2018$2.18B+8.9%
Q2 FY2018Jun 30, 2018$1.24B-7.9%
Q1 FY2018Mar 31, 2018$1.11B+93.0%
Q4 FY2017Dec 31, 2017$1.64B+40.2%
Q3 FY2017Sep 30, 2017$2.01B+64.7%
Q2 FY2017Jun 30, 2017$1.35B–
Q1 FY2017Mar 31, 2017$574.00M–
Q4 FY2016Dec 31, 2016$1.17B–
Q3 FY2016Sep 30, 2016$1.22B–

More Abbott Laboratories figures

See a number that looks wrong?